Summit Therapeutics Inc.
$25.12
$0.03(-0.12%)
Summit Therapeutics Inc.
SMMT
$25.12
$0.03(-0.12%)
Summit Therapeutics Inc.
SMMT
NASDAQ
$25.12
$0.03(-0.12%)
Chart
Upcoming Earnings
Next report date
May 7, 2026
Report period
Q2 2026
EPS Estimate
$-0.28
Revenue Estimate
$848.30K
Key stats
52-Week Range$25.12
$13.83
$36.91
Market capitalization
$19.48BDividend yield (indicated)
0.00%Price to earnings Ratio (TTM)
-17.42Basic EPS (TTM)
$-1.45Net income (TTM)
$-1.08BRevenue (TTM)
$0.00Avg. volume
2.65MBeta (1Y)
-1.37Employees
159Market capitalization
$19.48BDividend yield (indicated)
0.00%Price to earnings Ratio (TTM)
-17.42Basic EPS (TTM)
$-1.45Net income (TTM)
$-1.08BRevenue (TTM)
$0.00Avg. volume
2.65MBeta (1Y)
-1.37Employees
159Screener Quick Check
Sign in to check this stock against your screeners
Sign InAbout Summit Therapeutics Inc.
Sector
Healthcare
Industry
Biotechnology
CEO
Robert W. Duggan
Website
www.summittxinc.comHeadquarters
One Broadway, Cambridge, MA, 02142
IPO Date
2015-03-05
Identifiers
ISIN
US86627T1088Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in...
Related Stocks
$146.23
1D:
-1.6%
1Y:
300.0%
US76155X1000Healthcare
Mkt Cap
$28.98B
P/E Ratio TTM
-25.0
Revenue TTM
$0.00
Beta
1.01
Earnings TTM
$-1.13B
Dividend Yield TTM
0.00%
$54.59
1D:
1.6%
1Y:
117.2%
US60770K1079Healthcare
Mkt Cap
$21.56B
P/E Ratio TTM
-7.5
Revenue TTM
$1.94B
Beta
1.34
Earnings TTM
$-2.82B
Dividend Yield TTM
0.00%
Dividend Overview
This company does not pay dividends
Financials
Performance
Margin trends
Debt level and coverage
Earnings
Next: Q2 '26
Actual
Estimate
Performance
Margin trends
Debt level and coverage
Earnings
Next: Q2 '26
Actual
Estimate